Renal Denervation Hypertension After Stroke (REHEARSE)
It is known, that hypertension is the major risk factor of stroke and recurrent stroke. Blood pressure reduction - together with antithrombotics - remain crucial in stroke prevention.
This pilot study will examine the effect of renal nerve denervation in patients with treatment resistant hypertension after ischemic stroke or DWI/DTI-verified stroke. With 24 hours blood pressure measurements the effect after renal nerve denervation is examined 1,3,6 and 12 months after the procedure.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Pilot Study in Renal Denervation in Patients With Stroke and Uncontrolled Hypertension|
- 24 hour blood pressure [ Time Frame: 3 months ]
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||November 2014|
|Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
Radio frequent ablation is used to renal nerve denervation (RND) and is a new invasive method used in treatment for hypertensive patients, where the sympathetic nerves to the kidneys ablates. RND shows a significant reduction in the systolic and diastolic blood pressure in patients with treatment resistant hypertension.
The hypothesis is that RDN is able to reduce the blood pressure in patients with previous stroke and treatment resistant hypertension and thereby reduce the risk of a new stroke.
Aim of study:
- To validate the reduction in blood pressure after RND in patients with stroke and treatment resistant hypertension compared to the results achieved in patients only with essential hypertension
- To examine if this treatment is possible on patients after stroke (procedure related limitations and security of the patient)
- To describe the effect of RND in the development of changes in the white matter over time
Please refer to this study by its ClinicalTrials.gov identifier: NCT01689415
|Bispebjerg Hospital, Department of neurology|
|Copenhagen, Region H, Denmark, 2400|
|Principal Investigator:||Hanne Christensen, MD,Ph.D,DMSci||Bispebjerg Hospital - Department of neurology|